{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "17096298",
  "DateCompleted": {
    "Year": "2007",
    "Month": "01",
    "Day": "05"
  },
  "DateRevised": {
    "Year": "2020",
    "Month": "12",
    "Day": "09"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "1369-7056",
      "JournalIssue": {
        "Volume": "9",
        "Issue": "11",
        "PubDate": {
          "Year": "2006",
          "Month": "Nov"
        }
      },
      "Title": "IDrugs : the investigational drugs journal",
      "ISOAbbreviation": "IDrugs"
    },
    "ArticleTitle": "High unmet-need infectious disease opportunities.",
    "Pagination": {
      "StartPage": "774",
      "EndPage": "777",
      "MedlinePgn": "774-7"
    },
    "Abstract": {
      "AbstractText": [
        "Despite advances in pharmaceutical science, considerable unmet medical needs exist in the field of anti-infective therapies. While pharmaceutical companies have focused research efforts on a few selected areas of the field, new microbial diseases have steadily increased in prevalence. Three emerging areas in the field of anti-infectives now represent large commercial opportunities: Gram-negative infections, community-acquired methicillin-resistant Staphylococcus aureus, and Clostridium difficile-associated diarrhea. Dedication and extensive investment by pharmaceutical companies is required to battle against these emerging and deadly microbial infections."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Cubist Pharmaceuticals Inc, 65 Hayden Avenue, Lexington, MA 02421, USA. praveen.tipirneni@cubist.com"
          }
        ],
        "LastName": "Tipirneni",
        "ForeName": "Praveen",
        "Initials": "P"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "IDrugs",
    "NlmUniqueID": "100883655",
    "ISSNLinking": "1369-7056"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Infective Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Infective Agents"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Clostridioides difficile"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Community-Acquired Infections"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Design"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Enterocolitis, Pseudomembranous"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Gram-Negative Bacterial Infections"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Gram-Positive Bacterial Infections"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Methicillin Resistance"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Staphylococcal Infections"
    }
  ]
}